53rd week of 2015 patent applcation highlights part 24 |
Patent application number | Title | Published |
20150376202 | COMPOUND, MATERIAL FOR FORMING UNDERLAYER FILM FOR LITHOGRAPHY, UNDERLAYER FILM FOR LITHOGRAPHY AND PATTERN FORMING METHOD - The material for forming an underlayer film for lithography of the present invention contains a compound having a structure represented by the following general formula (1). | 2015-12-31 |
20150376203 | Protein Kinase C Inhibitors and Uses Thereof - This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 2015-12-31 |
20150376204 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS - Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed. | 2015-12-31 |
20150376205 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention provides a compound useful as an agent for the prophylaxis or treatment of neurodegenerative disease and the like, or a salt thereof. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof. | 2015-12-31 |
20150376206 | MACROCYCLIC PYRIDAZINONE DERIVATIVES - The present invention relates to compounds of formula (I) Wherein R1, R2, R3, R4, L and Z have the meaning given in claim | 2015-12-31 |
20150376207 | Substituted Phenyl Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds - The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, | 2015-12-31 |
20150376208 | MK2 INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 2015-12-31 |
20150376209 | METHOD AND DYES FOR DETECTING AND DESTROYING CANCER CELLS - This invention relates to new carbocyanine dye compositions, pharmaceutical compositions comprising such compositions, methods of detecting via near infrared fluorescent imaging incipient cancer cells and selective destruction of cancer cells identified by administration of such pharmaceutical compositions. A method of detecting and destroying cancer cells includes introducing a gold dye into an organism suspected of having a cancer cell. The gold dye is a carbocyanine dye covalently attached to a gold nanoparticle. A near infrared light is shined on a region suspected of having the cancer cell. Fluorescence from the gold dye is detected. A beam of radio frequency energy is directed at the region to induce hyperthermia in the cancer cell. The carbocyanine dye has the most basic structure of MHI-148 and structures 6 and 22 with a Au | 2015-12-31 |
20150376210 | BORON-CONTAINING SMALL MOLECULES - Compounds, pharmaceutical formulations, and methods of treating anti-inflammatory conditions and/or helminth-associated diseases are disclosed. | 2015-12-31 |
20150376211 | Si-CONTAINING FILM FORMING PRECURSORS AND METHODS OF USING THE SAME - Mono-substituted TSA precursor Si-containing film forming compositions are disclosed. The precursors have the formula: (SiH | 2015-12-31 |
20150376212 | FLAP MODULATORS - The present invention relates to compounds of Formula (I), or a form thereof wherein ring A | 2015-12-31 |
20150376213 | PHOSPHOLIPID COMPOUND CONTAINING UNSATURATED FATTY ACID DERIVATIVE HAVING CYCLOPROPANE RING - The invention provides a phospholipid compound containing unsaturated fatty acid having a cyclopropane ring such as 8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid (DCP-LA) and 8-(2-octylcyclopropyl)octanoic acid (DCP-OA) and the like, particularly 1,2-o-bis-[8-{2-(2-pentyl-cyclopropylmethyl)-cyclopropyl}-octanoyl]-sn-glycero-3-phosphatidylethanolamine (diDCP-LA-PE), which has a cognitive function improving effect and an anti-diabetes action, and which is useful as a medicine such as a therapeutic drug for dementia, a therapeutic drug for diabetes and the like. | 2015-12-31 |
20150376214 | HETEROCYCLYL-PYRIDINYL-BASED BIPHOSPHONIC ACID, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF - The present invention relates to novel compounds, compositions containing same and methods for inhibiting human farnesyl pyrophosphate synthase or for the treatment or prevention of disease conditions using said compounds; | 2015-12-31 |
20150376215 | Method Of Producing Phospholene Oxide - A method of producing a phospholene oxide is disclosed. A dihalohydrocarbylphosphine, 2-methyl-1,3-butadiene, and a halogenated hydrocarbon solvent are combined to form an adduct via an addition reaction in a homogenous system wherein the ratio of the 2-methyl-1,3-butadiene to the dihalohydrocarbylphosphine is from 1.0 to 2.0 and wherein the solvent is present in an amount of greater than 200 mL per mole of dihalohydrocarbylphosphine. The adduct is combined with alcohol and a carbonate or with a solution of metal hydroxide and water to form the phospholene oxide. | 2015-12-31 |
20150376216 | SUGAR-ANALOG PHOSPHORUS-CONTAINING HETEROCYCLES HAVING AN ANTI-METASTATIC ACTIVITY - The use of compounds of formula (1) as defined in the description, for reducing or preventing the onset of metastases in a patient suffering from cancer. Pharmaceutical compositions for using in human or veterinary medicine, including at least one compound of formula (1) are also described. | 2015-12-31 |
20150376217 | Organometallic Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device - As a novel substance having a novel skeleton, an organometallic complex with high emission efficiency which achieves improved color purity by a reduction of half width of an emission spectrum is provided. One embodiment of the present invention is an organometallic complex in which a β-diketone and a six-membered heteroaromatic ring including two or more nitrogen atoms inclusive of a nitrogen atom that is a coordinating atom are ligands. In General Formula (G1), X represents a substituted or unsubstituted six-membered heteroaromatic ring including two or more nitrogen atoms inclusive of a nitrogen atom that is a coordinating atom. Further, R | 2015-12-31 |
20150376218 | METHOD FOR MANUFACTURING NITROGEN-CONTAINING CARBON ALLOY, NITROGEN-CONTAINING CARBON ALLOY, AND FUEL CELL CATALYST - Provided is a method for manufacturing a nitrogen-containing carbon alloy having a sufficiently high oxygen reduction reaction activity, a nitrogen-containing carbon alloy, and a fuel cell catalyst. The method for manufacturing a nitrogen-containing carbon alloy comprises sintering a precursor which contains a nitrogen-containing compound and an inorganic metal salt, the nitrogen-containing compound having at least one heteroaromatic ring and a conjugated heterocycle, and the conjugated heterocycle having 12 or larger number of ring-forming atoms. | 2015-12-31 |
20150376219 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods - A process of regiospecific synthesis of N-9 purine nucleoside analogs in either solution or solid phase synthesis is described. The introduction of the sugar moiety or its analogue on to a 6-heteroarylium purine or its mesomeric betaine so that formation of only the N-9 position regioisomers of the purine nucleoside analogs (either D or L enantiomers) is obtained. This regiospecific introduction of the sugar moiety allows the synthesis of purine nucleoside analogs in high yields without formation of the N-7-positional regioisomers, while the 6-heteroaryliums are leaving groups facilitated for nucleophilic displacement. Solid supported 6-heterarylium purine bases can be used for purine based library synthesis and synthesis of nucleotide monophosphates and polyphosphates. Processes for providing novel 6-heteroarylium purines and their corresponding mesomeric betaines for the regiospecific synthesis of N-9 purine nucleoside analogs and nucleotides are described. | 2015-12-31 |
20150376220 | METHODS FOR PURIFICATION OF MESSENGER RNA - The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of (a) precipitating mRNA from an impure preparation; (b) subjecting the impure preparation comprising precipitated mRNA to a purification process involving membrane filtration such that the precipitated mRNA is captured by a membrane; and (c) eluting the captured precipitated mRNA from the membrane by re-solubilizing the mRNA, thereby resulting in a purified mRNA solution. In some embodiments, a purification process involving membrane filtration suitable for the present invention is tangential flow filtration. | 2015-12-31 |
20150376221 | Carbohydrate Phosphonate Derivatives as Modulators of Glycosylation - Compounds of Formula (I) are useful as modulators of glycosylation. Compounds of Formula (I) have the following structure: (I) and the definitions of the other variables are provided herein. | 2015-12-31 |
20150376222 | MACROLIDES USEFUL AS ANTICANCER AGENTS - The present invention relates to a compound of the following formula (I) or to a salt, hydrate, or pharmaceutically acceptable solvate thereof, in which R is a monosaccharide or disaccharide residue. The hydroxyl functions of the monosaccharide or disaccharide residue are, independently, optionally substituted for a (C | 2015-12-31 |
20150376223 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE - The present disclosure relates to the field of nucleic acid chemistry, specifically to 5-position modified uridines as well as phosphoramidite and triphosphate derivatives thereof. The present disclosure also relates to methods of making and using the same. | 2015-12-31 |
20150376224 | USE OF COMPOSITIONS OBTAINED BY CALCINING PARTICULAR METAL-ACCUMULATING PLANTS FOR IMPLEMENTING CATALYTICAL REACTIONS - The use of metal-accumulating plants for implementing chemical reactions especially catalytical reactions. | 2015-12-31 |
20150376225 | NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION - The present invention provides novel compounds of 11β-hydroxy steroids and compositions and their application as pharmaceuticals for preventing or reversing injury to mitochondria, for treating or preventing diseases relating to mitochondrial dysfunction or depletion, and for inducing regeneration or restructuring of mitochondria as a means of treating diseases relating to abnormalities in mitochondrial structure and function in a human or animal subject. Also disclosed herein are methods for diagnosing injury to mitochondria and for diagnosing the success or failure of therapeutics designed to treat, prevent, or reverse injury to or depletion of mitochondria. | 2015-12-31 |
20150376226 | ISOXAZOLIDINE DERIVATIVES - Glucocorticosteroids that are derivatives of isoxazolidine are useful as anti-inflammatory and antiallergic compounds of the glucocorticosteroid series. | 2015-12-31 |
20150376227 | LIGATION OF STAPLED POLYPEPTIDES - The present invention provides technology for making large (e.g., greater than 50 amino acids), semi-synthetic, stapled or stitched proteins. The method essentially involves ligating a synthetically produced stapled or stitched peptide to a larger protein. Modified version of IL-13 and MYC are provided as illustrative examples. | 2015-12-31 |
20150376228 | PROCESS FOR HIGH EFFICIENCY REFOLDING OF RECOMBINANT PROTEINS - A process of refolding a recombinant protein from inclusion bodies (IBs) formed inside a host cell, is provided. The process includes homogenising a wet cells slurry to obtain a cell lysate; incubating the cell lysate with a reducing agent to obtain a reduced cell lysate; isolating reduced IBs from the reduced cell lysate to obtain isolated IBs; solubilising the isolated IBs with a denaturing agent to obtain solubilised IBs; and subjecting the solubilised IBs to a unit process of refolding to obtain a refolded recombinant protein. | 2015-12-31 |
20150376229 | TANGENTIAL FLOW FILTRATION BASED PROTEIN REFOLDING METHODS - Provided herein are methods for refolding proteins that are denatured. Exemplary methods comprise solubilizing the denatured protein with a denaturing agent, e.g., a chaotropic agent, and renaturing the protein using a buffer exchanging system, e.g., tangential flow filtration (TFF). | 2015-12-31 |
20150376230 | METHODS FOR REDUCING AGGREGATE LEVELS IN PROTEIN PREPARATIONS BY TREATMENT WITH THIO-HETEROCYCLIC CATIONS - A method of reducing the aggregate content in a protein preparation having a target protein includes contacting the protein preparation with a thio-heterocyclic cation to form a mixture, contacting the mixture with at least one functionalized solid to remove excess thio-heterocyclic cations; and optionally contacting the mixture, simultaneously or sequentially, with at least one further functionalized solid to further reduce aggregate content of the protein preparation. | 2015-12-31 |
20150376231 | PROTEIN PURIFICATION METHODS - A method for the purification of a desired protein from a protein preparation includes conditioning the protein preparation by treatment with soluble organic multivalent ions, immobilized organic multivalent ions, or both, optionally in the presence of supersaturated allantoin, thereby removing at least 90% of chromatin, then (1) precipitating the desired protein with a nonionic organic polymer in the presence of non-protein-precipitating salts at greater than physiological concentration to provide a precipitate of the desired protein; or (2) precipitating the desired protein with a nonionic organic polymer in the absence of non-precipitating salts at greater than physiological concentration to provide a precipitate and subsequently washing the precipitate with a nonionic organic polymer in the presence of non-protein-precipitating salts at greater than physiological concentration. | 2015-12-31 |
20150376232 | SELECTIVE REMOVAL OF A PROTEIN FROM A MIXTURE OF PROTEINS USING ACTIVATED CARBON BY ADJUSTING SOLUTION CONDITIONS - The present invention provides novel and improved protein purification processes which incorporate certain types of carbonaceous materials and result in effective and selective removal of certain undesirable impurities without adversely effecting the yield of the desired protein product. | 2015-12-31 |
20150376233 | HEPATITIS C VIRUS INHIBITORS - Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed. | 2015-12-31 |
20150376234 | SHORT PEPTIDES AND A METHOD OF USE AS AN ANTIOXIDANT - A short chain polypeptide having antioxidant activity is provided. The short chain polypeptide has 2 to 4 amino acids bonded to form a polypeptide chain having an amine-terminal end and a carboxyl terminal end; wherein a net charge of the short chain polypeptide is positive, the amino terminal amino acid is an amino acid selected from the group consisting of arginine, lysine and histidine, the polypeptide chain following from the amino terminus comprises a hydrophobic or neutral amino acid, and the polypeptide chain is free of an amino acid having a negatively charged side-chain group. A method to prepare a composition having antioxidant activity and a composition having antioxidant activity are also provided. | 2015-12-31 |
20150376235 | Peptides for the Treatment of Immune Reconstitution Inflammatory Syndrome (IRIS) and Related Diseases - A method of treatment of Immune Reconstitution Inflammatory Syndrome (IRIS) in a patient is disclosed. The method comprises preparing a composition comprising a D peptide and a pharmaceutically acceptable carrier.,said D peptide further comprises the general structure: A-B-C-D-E-F-G-H in which:
| 2015-12-31 |
20150376236 | PEPTIDOMIMETICS POSSESSING PHOTO-CONTROLLED BIOLOGICAL ACTIVITY - The present invention relates to pharmaceutically and/or diagnostically active compounds, in particular peptide analogues (peptidomimetics), which can be reversibly controlled between an active and an inactive state by irradiation with light of different wavelengths. The present invention further relates to an intermediate compound usable in the manufacture of such pharmaceutically and/or diagnostically active compounds, as well as a manufacturing method thereof. | 2015-12-31 |
20150376237 | POLYPEPTIDES FOR BLOOD BRAIN BARRIER TRANSPORT - The present invention provides polypeptides that cross the blood brain barrier (BBB). These polypeptides are therefore BBB transport agents. The polypeptides are typically able to cross the BBB at a level effective to be therapeutically or diagnostically useful or physiologically significant, either alone or when coupled to a therapeutic or diagnostic agent. | 2015-12-31 |
20150376238 | Polypeptides for Treating and/or Limiting Influenza Infection - Disclosed herein are polypeptides that bind to the hemagglutinin protein of influenza virus, and which can be used for treating and diagnosing influenza infection. | 2015-12-31 |
20150376239 | USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS - The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid. | 2015-12-31 |
20150376240 | ENHANCED AAV-MEDIATED GENE TRANSFER FOR RETINAL THERAPIES - Described herein are capsid proteins and adeno-associated viruses capable of targeting various types of ocular cells including bipolar and horizontal cells. Also described herein are methods of treating various ocular disorders in a subject in need thereof by administering to the subject an effective concentration of a composition comprising the recombinant adeno-associated virus (AAV) of the invention. | 2015-12-31 |
20150376241 | FLAGELLIN RELATED POLYPEPTIDES AND USES THEREOF - The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptosis is described. | 2015-12-31 |
20150376242 | Modified Streptococcus Pneumoniae Pneumolysin (PLY) Polypeptides - This disclosure relates to immunogenic compositions comprising mutant | 2015-12-31 |
20150376243 | Use of AXMI184 for the Control of Rootworm Insects - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. In particular, methods for killing or controlling a coleopteran pest population, particularly a corn rootworm pest population, are provided. The methods include contacting the coleopteran pest with a pesticidally-effective amount of a polypeptide comprising a coleopteran toxin, particularly a corn rootworm toxin. Further included are methods for increasing yield in plants by expressing the toxin of the invention. | 2015-12-31 |
20150376244 | AXMI115 VARIANT INSECTICIDAL GENE AND METHODS FOR ITS USE - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. The toxin coding sequences can be used in DNA constructs or expression cassettes for expression in plants and bacteria. Compositions include transformed bacteria, plants, plant cells, tissues, and seeds. In particular, polynucleotide sequences and the toxin proteins encoded thereby are provided. Also provided are antibodies specifically binding to those amino acid sequences. In particular, the invention encompasses nucleotide sequences encoding fusion proteins, as well as biologically active variants and fragments thereof, wherein the fusion protein contains the C-terminal portion of SEQ ID NO:43. The fusion protein may also contain the N-terminal portion of SEQ ID NO:45. The invention also includes the nucleotide sequence of SEQ ID NO:47 and 1-14, or a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO:2, 3, 7-14 and 47, including biologically active variants and fragments thereof. | 2015-12-31 |
20150376245 | METHODS AND COMPOSITIONS RELATING TO CRM197 - The present invention provides novel methods of producing diphtheria toxin. In particular, the present invention provides novel methods of producing nontoxic forms of diphtheria toxin, e.g., CRM197. The present invention also provides novel compositions comprising diphtheria toxin or nontoxic forms of diphtheria toxin, e.g., CRM197. | 2015-12-31 |
20150376246 | HIGH AFFINITY DIGOXIGENIN BINDING PROTEINS - Isolated polypeptides with steroid binding activity and methods for their use as therapeutics and detection agents are disclosed herein. | 2015-12-31 |
20150376247 | POLYPEPTIDE PARTICLE AND METHOD FOR PRODUCING SAME - Polypeptide particles of the present invention are particles of a polypeptide derived from spider silk proteins, and have an average particle size of 1000 nm or less. A method for producing polypeptide particles of the present invention includes: a solution production step in which the polypeptide is dissolved in at least one solvent selected from the group consisting of DMSO, DMF, and these with an inorganic salt, so as to obtain a solution of the polypeptide; a step in which the solution produced in the solution production step is substituted with a water-soluble solvent so as to obtain an aqueous solution of the polypeptide; and a step in which the aqueous solution of the polypeptide is dried. Thereby, the present invention provides polypeptide particles suitable for application to a living body and capable of being applied to cosmetics, etc., while identifying the properties of the polypeptide particles, and a method for producing the same. | 2015-12-31 |
20150376248 | PHOTOACTIVE SILK PROTEIN AND FABRICATION OF SILK PROTEIN STRUCTURES USING PHOTOLITHOGRAPHY - A natural protein, specifically silk fibroin or sericin, is chemically modified such that it can be rendered photoactive, but which otherwise has similar structure and attributes as silk fibroin or sericin. This chemically modified silk conjugate can be patterned using radiant energy to produce patterned silk materials which may be used for a wide variety of applications such as making micro and nanoparticles of different shapes and functionalities for drug delivery, creating new forms of intricate 3D scaffolds for tissue engineering, and forming substrates for flexible bio-electronics. | 2015-12-31 |
20150376249 | METHODS FOR INCREASING N-GLYCAN OCCUPANCY AND REDUCING PRODUCTION OF HYBRID N-GLYCANS IN PICHIA PASTORIS STRAINS LACKING ALG3 EXPRESSION - Methods are disclosed for increasing the yield and N-glycosylation site occupancy of paucimannose or complex N-glycans of recombinant glycoproteins produced in a recombinant host cell lacking dolichyl-P-Man:Man | 2015-12-31 |
20150376250 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF OXYGEN - H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O | 2015-12-31 |
20150376251 | Method for Inducing Formation of Neurons from Embryonal Stem Cells - A method is described for inducing formation of neurons from embryonal stem cells, by utilizing an exogenous ferritin-H inducer. | 2015-12-31 |
20150376252 | Norrin Mutant Polypeptides, Methods of Making and Uses Thereof - The present invention relates to Norrin mutant polypeptides that inhibit or reduce angiogenesis in various tissues. Methods for synthesizing recombinant Norrin and Norrin mutant polypeptides are provided. Methods of inhibiting or reducing aberrant angiogenesis comprise contacting a tissue undergoing aberrant angiogenesis with a composition comprising an isolated Norrin C mutant polypeptide. | 2015-12-31 |
20150376253 | CD40 Agonist Antibody /Type 1 Interferon Synergistic Adjuvant Combination, Conjugates Containing and Use Thereof as a Therapeutic to Enhance Cellular Immunity - A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided. | 2015-12-31 |
20150376254 | GAMMA-MSH ANALOGUES - The present invention provides peptide analogues of γ-MSH, comprising the amino acid sequence of human γ-MSH, or variants thereof, and having one or two linear amino acid probe(s) in the N- and/or C-terminal part of the peptide. | 2015-12-31 |
20150376255 | AQUARETIC AND NATRIURETIC POLYPEPTIDES LACKING VASODILATORY ACTIVITY - This document provides aquaretic and natriuretic polypeptides. For example, this document provides polypeptides having aquaretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have aquaretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing aquaretic and/or natriuretic activities within a mammal. | 2015-12-31 |
20150376256 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS - Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon. | 2015-12-31 |
20150376257 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain and for treating diabetes and associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptide compounds effective in such methods. The compounds may mediate their effect by having, for example, increased selectivity for the GLP-1 receptor compared to human glucagon. | 2015-12-31 |
20150376258 | USE OF CD31 PEPTIDES IN THE TREATMENT OF THROMBOTIC AND AUTOIMMUNE DISORDERS - The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. The invention relates to peptides corresponding to fragments of CD31 that inhibit T-cell response, and to their use in the treatment of thrombotic disorders such as atherothrombosis and autoimmune disorders. | 2015-12-31 |
20150376259 | COMPOSITIONS AND METHODS FOR ENHANCING ODORANT RECEPTOR ACTIVITY - The present invention relates to polypeptides capable of modulating odorant receptor activation. In particular, the present invention provides polypeptides (e.g., type 3 muscarinic actetylcholine receptor M3) capable of enhancing odorant receptor activation. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for polypeptide polymorphisms and mutations associated with odorant receptor activation (e.g., polymorphisms and mutations associated with muscarinic actetylcholine receptor polypeptides (e.g., M1, M2, M3, M4, M5)), as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins. | 2015-12-31 |
20150376260 | Stable Form Of Signal Converting Protein Fusion Proteins, And Methods Of Use And Preparation Thereof - A stable fusion protein, wherein in solution, a majority of the fusion proteins are in the homo-hexamer form, which may be prepared for example as a CTLA4-FasL fusion protein. | 2015-12-31 |
20150376261 | NOVEL CHIMERIC POLYPEPTIDES FOR SCREENING AND DRUG DISCOVERY PURPOSES - Described are polypeptides and their use for screening and drug discovery. More specifically, the disclosure provides chimeric polypeptides comprising a membrane protein, in particular a GPCR, fused to a binding domain, wherein the binding domain is directed against and/or specifically binds to the membrane protein. In particular, the chimeric polypeptides are single proteins wherein, in an intramolecular reaction, the binding domain stabilizes the membrane protein in a conformation of interest. Also provided are nucleic acid sequences encoding such chimeric polypeptides, cells capable of expressing such chimeric polypeptides as well as cellular compositions derived thereof. Also screening methods for compounds using the chimeric polypeptides. | 2015-12-31 |
20150376262 | Factor VIII Molecules With Reduced VWF Binding - The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group. | 2015-12-31 |
20150376263 | Methods, Compositions and Systems for Production of Recombinant Spider Silk Polypeptides - Disclosed are methods, compositions, and systems for transforming silkworms to produce spider silk and analogs of spider silk. In certain embodiments, the method may include inserting a DNA sequence coding for at least a portion of a spider silk fibroin polypeptide, or an analog of a spider silk fibroin polypeptide, positioned between at least a portion of the 5′ and 3′ ends of a silkworm fibroin gene to generate a fusion gene construct having a sequence that encodes for a polypeptide comprising both spider silk fibroin and silkworm silk fibroin sequences. In certain embodiments, the fused gene is able to replace a native gene present in the silkworm such that the transformed silkworm expresses a polypeptide comprising a spider silk fibroin polypeptide, or an analog thereof, and expresses significantly less of the native silkworm silk. | 2015-12-31 |
20150376264 | BOVINE FUSION ANTIBODIES - Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject. | 2015-12-31 |
20150376265 | ANTIBODY COMPOSITIONS AND METHODS OF USE - The invention provides compositions comprising anti-gH antibodies and anti-Complex I antibodies as well as methods of using the same. | 2015-12-31 |
20150376266 | GRAM-POSITIVE BACTERIA SPECIFIC BINDING COMPOUNDS - The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals. | 2015-12-31 |
20150376267 | HUMAN ANTIBODIES TO HUMAN DELTA LIKE LIGAND 4 - The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the K | 2015-12-31 |
20150376268 | ANTIBODIES TO OXIDIZED PHOSPHOLIPIDS - The disclosure provides for single chain variable fragments to oxidized phospholipid epitopes and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents for treating CAS. | 2015-12-31 |
20150376269 | HUMAN ANTIBODIES TO SERUM RESISTANCE-ASSOCIATED PROTEIN FROM TRYPANOSOMA BRUCEI RHODESIENSE - The present invention provides antibodies that bind to serum resistance-associated (SRA) protein of | 2015-12-31 |
20150376270 | TREATMENT METHOD FOR LUNG REMODELING DISEASES - The present invention relates to methods and medicaments useful for pre-treatment, treatment, or amelioration of lung remodeling disease. Methods and medicaments for reducing, preventing, or reversing increased lung density, improving lung function, and increasing survivability in subjects having lung remodeling disease are also provided. | 2015-12-31 |
20150376271 | DUAL PDGF/VEGF ANTAGONISTS - The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration. | 2015-12-31 |
20150376272 | INHIBITION OF ANGIOGENESIS IN REFRACTORY TUMORS - The present invention relates generally to the inhibition of tumor angiogenesis. In particular, the invention concerns the prevention or treatment of tumor angiogenesis and the suppression of tumor growth in tumors refractory to an anti-vascular endothelial growth factor (VEGF) treatment, using IL-17 antagonists, such as anti-IL-17 antibodies and other antagonists. | 2015-12-31 |
20150376273 | ANTIBODIES TO NTB-A - Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NTB-A. | 2015-12-31 |
20150376274 | TREATMENT OF PERIPHERAL T CELL LYMPHOMA - The present disclosure relates to methods for the treatment, prevention and diagnostic of peripheral T cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express at their surface NKp46, and pharmaceutical compositions comprising the same. The disclosure also relates to use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma. | 2015-12-31 |
20150376275 | ANTI-KIR ANTIBODIES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISORDERS - This invention relates to compounds that inhibit KIR2DL1, 2 and/or 3 polypeptide comprising compounds (e.g., anti-KIR2DL1, 2, and/or 3 antibodies) that neutralize NK cell inhibitory receptors and methods of using such compounds and compositions containing in the treatment and prevention of inflammatory or autoimmune disorders. | 2015-12-31 |
20150376276 | ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODS - Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells. Further disclosed is a method of treating multiple myeloma using an anti-NTB-A antibody drug conjugate, which optionally includes an anti-NTB-A antibody as disclosed herein. | 2015-12-31 |
20150376277 | ANTI-CD83 ANTIBODIES AND USE THEREOF - The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis, or prognosis. | 2015-12-31 |
20150376278 | USE OF A CD28 BINDING PHARMACEUTICAL SUBSTANCE FOR MAKING A PHARMACEUTICAL COMPOSITION WITH DOSE-DEPENDENT EFFECT - The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (MAB) or of a mimetic compound of the same, for producing a pharmaceutical composition, wherein the dosage is below or above a defined dosage limit. | 2015-12-31 |
20150376279 | CELL PENETRATING NUCLEOLYTIC ANTIBODY BASED CANCER THERAPY - Cancer cells with defects in DNA repair are highly susceptible to DNA-damaging agents, but delivery of therapeutic agents into cell nuclei can be challenging. A sub-set of autoantibodies having nucleolytic activity are capable of nuclear penetration. These antibodies can be used as therapeutic agents targeted towards DNA repair-deficient malignancies. | 2015-12-31 |
20150376280 | ANTI-INFLAMMATORY POLYPEPTIDES - This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders. | 2015-12-31 |
20150376281 | Use of NKG2D Inhibitors for Treating Cardiovascular and Metabolic Diseases, Such as Type 2 Diabetes - The present invention provides methods, compositions and kits for treating and detecting type 2 diabetes and/or conditions that may be regulated or normalised via inhibition of NKG2D, such as cardiovascular diseases. | 2015-12-31 |
20150376282 | ANTIBODY VARIANTS HAVING MODIFICATIONS IN THE CONSTANT REGION - The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed. | 2015-12-31 |
20150376283 | FGFR1 AGONISTS AND METHODS OF USE - The invention provides FGFR1 agonists, including agonistic anti-FGFR1 antibodies, and methods of using the same. | 2015-12-31 |
20150376284 | ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF - Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed. | 2015-12-31 |
20150376285 | Antibody Molecule For Human GM-CSF Receptor Alpha - Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFRα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis. | 2015-12-31 |
20150376286 | HUMAN CGRP RECEPTOR BINDING PROTEINS - Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches. | 2015-12-31 |
20150376287 | BISPECIFIC ANTIBODIES AGAINST CD3 AND BCMA - A bispecific antibody specifically binding to the two targets human CD3ε and human BCMA, wherein the variable domains of one antibody portion are replaced by each other, and characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-κB activation, BAFF-dependent NF-κB activation, and does not alter NF-κB activation without BAFF and APRIL is useful as a therapeutic agent. | 2015-12-31 |
20150376288 | CD47 Targeted Therapies for the Treatment of Infectious Disease - Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRPα on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells. | 2015-12-31 |
20150376289 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER - Methods and compositions are provided for the diagnosis and treatment of lung cancers in particular NSCLC associated with amplification or overexpression of the PRO gene, i.e. any of PDGFRA, KIT or KDR. | 2015-12-31 |
20150376290 | ANTIBODIES SPECIFIC FOR CLL-1 - Provided herein are antibodies specific for CLL-1. | 2015-12-31 |
20150376291 | ANTI C-MET ANTIBODIES - The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein. | 2015-12-31 |
20150376292 | ANTI C-MET ANTIBODIES - The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein. | 2015-12-31 |
20150376293 | Methods of Producing Antibodies Specific for p95 - The invention provides methods of measuring and/or quantifying the presence and/or amount of p95 and/or p95 complex in a sample. The invention also provides antibodies specific for p95, and methods of making such antibodies. | 2015-12-31 |
20150376294 | ANTI-PAD2 ANTIBODIES AND TREATMENT OF AUTOIMMUNE DISEASES - The present invention relates to anti-peptidylarginine deiminase 2 (PAD2) antibodies and anti-PAD2 antibodies for use in the treatment of autoimmune diseases characterized by extracellular citrullination, such as rheumatoid arthritis (RA). The invention further relates to a method for treatment of an autoimmune disease characterized by extracellular citrullination comprising the administration of a suitable amount of an anti-PAD2 antibody to a subject. | 2015-12-31 |
20150376295 | Humanized Anti-Factor D Antibodies And Uses Thereof - The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease. | 2015-12-31 |
20150376296 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY - The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing an antigen recognizing receptor and an inhibitory chimeric antigen receptor (iCAR). Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired. | 2015-12-31 |
20150376297 | METHOD FOR REFOLDING ANTIBODY, PROCESS FOR PRODUCING REFOLDED ANTIBODY, REFOLDED ANTIBODY, AND USES THEREOF - A method for refolding an antibody, a process for producing a refolded antibody, a refolded antibody, and uses thereof are provided. A method for refolding an antibody in a liquid phase comprises the steps of denaturing an inactive antibody binding directly or through a linker to a peptide, the peptide having an isoelectric point lower than the isoelectric point of the inactive antibody, and dispersing in a liquid phase the peptide-binding inactive antibody denatured in the step above. Also provided is a process for producing a refolded antibody. | 2015-12-31 |
20150376298 | MODIFIED NANOCELLULOSE, AND RESIN COMPOSITION CONTAINING MODIFIED NANOCELLULOSE - The present invention provides a novel modified nanocellulose suitable for surface modification of nanocellulose or introduction of functional groups into nanocellulose, and a resin composition comprising the modified nanocellulose. More specifically, the present invention provides a modified nanocellulose in which a portion of the hydroxyl groups of cellulose constituting nanocellulose is substituted with at least one substituent represented by formula (1), and a resin composition comprising the modified nanocellulose and a resin. | 2015-12-31 |
20150376299 | NOVEL ESTERIFIED CELLULOSE ETHERS OF VERY LOW VISCOSITY - An esterified cellulose ether which comprises (i) aliphatic monovalent acyl groups or (ii) groups of the formula —C(O)—R—COOA, wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation, or (iii) a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA, and which has a) a viscosity of from 1.2 to 1.8 mPaos, measured as a 2.0 wt % solution of the esterified cellulose ether in 0.43 wt % aqueous NaOH at 20° C., or b) a viscosity of up to 5 mPa·s, measured as a 10 wt % solution of the esterified cellulose ether in acetone at 20° C., or c) a combination of the viscosities of a) and b), is useful for preparing solid dispersions comprising drugs. | 2015-12-31 |
20150376300 | BIODEGRADABLE SUPERABSORBENT HYDROGELS - The present invention is directed to natural polymer-based biodegradable superabsorbent hydrogels and to methods for making them. These hydrogels can be employed in hygienic-health products, in the sector of food product packaging and in medical products. | 2015-12-31 |
20150376301 | METHOD OF PREPARING FIBRE-CONTAINING PECTIN PRODUCT AND PECTIN PRODUCTS HEREOF - The present invention relates to a method for providing a fibre-containing pectin product from a plant material. The method comprises the steps of: (i) providing a plant material comprising pectin, where said pectin is having a degree of esterification of 55% or less, (ii) adding an acidic aqueous solution to the pectin containing plant material obtained in step (i) and providing a suspension of the plant material, where the suspended plant material provides an in situ system by swelling the plant material under conditions where the pectin is kept within the plant material, and (iii) obtaining the fibre-containing pectin product from the suspension provided in step (ii), wherein the plant material is substantially depleted from divalent cations. | 2015-12-31 |